Want to see EVGN full AI Analyst Report?
Top Page
Evogene
(NASDAQ:EVGN)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.39
▼(-29.09% Downside)
Action:Reiterated
Date:09/30/26
The score is driven primarily by very weak financial performance—large ongoing losses, shrinking revenue, persistent free-cash-flow burn, and negative equity implying elevated financing/solvency risk. Technicals add further downside pressure as the price is below all key moving averages and momentum remains negative. Valuation provides limited support because the company is unprofitable (negative P/E) and no dividend yield is available.
Positive Factors
AI platform expansion and collaboration traction
Expansion of ChemPass and a growing set of active collaborations provide evidence that Evogene’s computational biology platform is gaining commercial validation. Progressing partnered programs can support future milestone, licensing, or royalty opportunities while increasing the platform’s strategic relevance.
Negative Factors
Deep losses and shrinking revenue
Evogene’s very small and declining revenue base remains insufficient to cover operating expenses, resulting in deeply negative earnings and margins. This weak operating leverage makes profitability dependent on successful program advancement, partnerships, or commercialization rather than an established recurring revenue engine.
Read all positive and negative factors
Positive Factors
Negative Factors
AI platform expansion and collaboration traction
Expansion of ChemPass and a growing set of active collaborations provide evidence that Evogene’s computational biology platform is gaining commercial validation. Progressing partnered programs can support future milestone, licensing, or royalty opportunities while increasing the platform’s strategic relevance.
Read all positive factors
Evogene (EVGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.81M
Dividend YieldN/A
Average Volume (3M)2.56M
Price to Earnings (P/E)―
Beta (1Y)0.80
Revenue Growth-80.59%
EPS Growth59.44%
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.91
Shares Outstanding15,801,407
10 Day Avg. Volume181,049
30 Day Avg. Volume2,563,864
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-105.63
Price to Sales (P/S)2.25
P/FCF Ratio-0.64
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue5.34
Enterprise Value/Gross Profit-4.31
Enterprise Value/Ebitda-0.56
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$1.48M
Evogene Business Overview & Revenue Model
Company Description
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveragi...
How the Company Makes Money
Evogene primarily makes money through (1) collaboration and licensing arrangements and (2) advancing internally developed programs that can be partnered or commercialized. Under collaborations, Evogene may provide access to its computational disco...
Evogene Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Neutral
The call communicated substantial operational and technological progress: a focused shift to ChemPass, meaningful cost and headcount reductions, important platform upgrades (AI agents, predictive models), expanded virtual chemical space, and multiple collaboration agreements validating the platform. These positives are tempered by significant near-term financial and commercialization challenges — materially lower revenue versus prior year, a limited cash balance relative to expected burn, noncash warrant-related accounting volatility, program discontinuation (APTH1), and shareholder governance pressure. Management highlighted actions to raise capital, monetize noncore assets, expand investor outreach, and pursue partnerships, but timelines to convert technological progress into material revenue remain uncertain.Positive Updates
Strategic Transformation to AI-Driven Organization
Company transformed into a lean, AI-driven leader focused on computational chemistry (ChemPass). Headcount reduced from 117 to 38 (≈67.5% reduction) and cash burn reduced from ~$20.5M in 2024 to an expected $8.5–$9.5M in 2026 (≈53–63% reduction).
Negative Updates
Significant Revenue Decline
Revenues for H1 2026 were ~$0.7M vs ~$2.9M in H1 2025, a decrease of approximately $2.2M (~-76%). Q2 revenue declined to ~$0.3M from ~$0.5M in Q2 2025 (~-40%), primarily due to lower Casterra sales and conclusion of the AgPlenus agreement with Bayer.
Read all updates
Q2-2026 Updates
Positive
Negative
Strategic Transformation to AI-Driven Organization
Company transformed into a lean, AI-driven leader focused on computational chemistry (ChemPass). Headcount reduced from 117 to 38 (≈67.5% reduction) and cash burn reduced from ~$20.5M in 2024 to an expected $8.5–$9.5M in 2026 (≈53–63% reduction).
Read all positive updates
Company Guidance
Management reiterated financial and operational guidance: full‑year 2026 consolidated cash usage is expected to be approximately $8.5–$9.5 million (Q2 cash usage ~$2.1M; cash & cash equivalents as of June 30, 2026 ~$9.3M) with further burn reductions anticipated in 2027 after lowering burn from ~ $20.5M in 2024 to the 2026 guidance; headcount has been cut from 117 to 38 and ~ $11.1M in new capital was raised (ATM proceeds ~ $0.8M in Q2 and ~$2.4M in Q3 2026); H1 2026 revenue was ~$0.7M (Q2 ~$0.3M) vs. $2.9M in H1 2025, net loss Q2 2026 was ~$1.8M (vs. $4.7M Q2 2025) and net loss H1 2026 was ~ $7.7M, R&D (net of grants) H1 ~$2.9M (Q2 ~$1.4M), S&M H1 ~$0.7M (Q2 ~$0.3M), G&A H1 ~$2.0M (Q2 ~$0.9M), financing results affected by warrant accounting (H1 recorded ~ $3.8M of finance expense and ~$2.1M of financing income), loss from discontinued operations H1 ~$0.5M (Q2 ~$0.2M); operational targets include monetization and advancement of ChemPass (virtual chemical space expanded from 36B to 110B molecules, 6 active collaborations—4 signed this year—with Hit ID completed in 2, internal programs advanced from Hit‑to‑Lead to Lead Optimization/step 3 and an anticipated move into preclinical for at least one program in H2 2027, and an Ag Septoria fungicide program nearing completion of step 3 ahead of greenhouse and field trials).Evogene Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
24
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.31M | 3.85M | 5.58M | 2.98M | 1.68M | 930.00K |
| Gross Profit | -1.62M | -241.00K | 3.20M | 1.49M | 766.00K | 163.00K |
| EBITDA | -12.56M | -12.20M | -13.36M | -20.53M | -27.01M | -27.88M |
| Net Income | -9.07M | -8.48M | -16.48M | -23.88M | -26.64M | -27.79M |
Balance Sheet | ||||||
| Total Assets | 13.44M | 20.05M | 39.86M | 51.10M | 56.13M | 76.30M |
| Cash, Cash Equivalents and Short-Term Investments | 9.35M | 12.96M | 15.31M | 31.06M | 35.35M | 53.87M |
| Total Debt | 2.10M | 2.20M | 12.87M | 11.51M | 11.93M | 2.67M |
| Total Liabilities | 7.67M | 8.07M | 25.03M | 22.42M | 21.34M | 12.88M |
| Stockholders Equity | -3.29M | -82.00K | -1.45M | 12.05M | 27.93M | 53.65M |
Cash Flow | ||||||
| Free Cash Flow | -11.56M | -13.64M | -20.33M | -22.36M | -24.85M | -25.56M |
| Operating Cash Flow | -11.54M | -13.50M | -19.70M | -21.58M | -23.68M | -24.84M |
| Investing Cash Flow | 21.66M | 17.74M | 9.62M | -4.54M | 13.27M | -20.44M |
| Financing Cash Flow | -9.71M | -6.60M | 4.66M | 18.15M | 9.34M | 30.28M |
Evogene Technical Analysis
Negative
0.55
Price Trends
0.50
Negative
0.52
Negative
0.70
Negative
Market Momentum
-0.03
Negative
40.59
Neutral
27.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVGN, the sentiment is Negative. The current price of 0.55 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.50, and below the 200-day MA of 0.70, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 40.59 is Neutral, neither overbought nor oversold. The STOCH value of 27.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EVGN.
Evogene Risk Analysis
Evogene disclosed 62 risk factors in its most recent earnings report. Evogene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Evogene Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $27.77M | -0.54 | -61.39% | ― | 134.15% | 82.33% | |
43 Neutral | $5.49M | ― | 762.51% | ― | 135.52% | 85.50% | |
41 Neutral | $6.74M | -0.85 | -237.91% | ― | ― | 23.05% | |
41 Neutral | $2.18M | -0.07 | 89.25% | ― | -22.73% | 53.53% | |
40 Underperform | $5.81M | -0.41 | 761.97% | ― | -80.59% | 59.44% | |
40 Underperform | $7.06M | -0.13 | -1539.97% | ― | ― | 80.28% |
* Healthcare Sector Average
EVGN
Evogene
0.37
-0.89
-70.79%
JAGX
Jaguar Animal Health
2.82
-832.60
-99.66%
XCUR
Exicure
1.03
-3.69
-78.18%
BCAB
BioAtla
1.31
-29.39
-95.73%
EVAX
Evaxion Biotech
3.33
-3.76
-53.03%
SNTI
Senti Biosciences
0.23
-1.91
-89.44%
Evogene Corporate Events
Evogene Wins Nasdaq Extension to March 2027 to Fix Minimum Bid Price
Sep 30, 2026
On September 30, 2026, Evogene reported it had received a letter from Nasdaq granting an additional 180-day grace period, until March 29, 2027, to regain compliance with the exchange’s $1.00 minimum bid price requirement for its ordinary sha...
Evogene Updates SEC Filings With Weakening Mid-2026 Balance Sheet
Sep 28, 2026
On September 28, 2026, Evogene filed a Form 6-K with the U.S. Securities and Exchange Commission, furnishing unaudited condensed consolidated financial statements for the six months ended June 30, 2026. The filing also includes an operating and fi...
Evogene Faces Dissident Shareholder Tender Offer and Board Resignations After September AGM
Sep 15, 2026
Following its Annual General Meeting held on September 4, 2026, Evogene Ltd. disclosed that two shareholders, L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd., challenged the published voting results and, on September 8, 2026, notified the ...
Evogene Confirms Board Slate at September 4 Shareholder Meeting
Sep 4, 2026
On September 4, 2026, Evogene Ltd. held its annual general meeting of shareholders at its offices in Rehovot, Israel, at which a quorum was present and key corporate resolutions were put to vote. Shareholders approved Proposals 1(a) and 2-4, resul...
Evogene Updates U.S. Investors With New August 2026 Presentation
Aug 27, 2026
Evogene Ltd., an Israel-based biotechnology company and foreign private issuer in the U.S., focuses on computational biology-driven solutions for the life-sciences sector. Its investor materials indicate activity in major therapeutic areas such as...
Evogene Deepens AI-Driven Transformation as Second-Quarter Loss Narrows and ChemPass Platform Expands
Aug 18, 2026
On August 18, 2026, Evogene reported its second-quarter and first-half 2026 results, highlighting the impact of its strategic shift toward AI-driven computational chemistry for pharma and crop protection. The company cut its quarterly net loss to ...
Evogene Sets Sept. 4 AGM Amid Board Contest and VP Departure
Jul 31, 2026
Evogene announced on July 31, 2026 that it will hold its annual general meeting of shareholders on September 4, 2026 at its Rehovot headquarters, with shareholders of record as of August 11 eligible to vote. The meeting agenda includes choosing be...
Evogene Expands ATM Offering as Shareholder Activism Escalates
Jul 18, 2026
Evogene Ltd. has increased the maximum aggregate size of its at-the-market equity offering program, raising the cap on ordinary shares that may be sold under its June 11, 2026 Sales Agreement with A.G.P./Alliance Global Partners from $2.93 million...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.